Celecoxib decreases post-operative pain and lowers morphine consumption after TKR .
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2013;1(11):94 Acta Orthop. 2007 Oct;78(5):661-750 patients requiring total knee replacement (TKR) were randomized to receive either a placebo, or Celecoxib (200mg) preoperatively and twice daily for 3 weeks postoperatively. The primary outcome examined was perioperative blood loss, and other subjective factors were reviewed. Results demonstrated that Celecoxib does not increase perioperative blood loss, but decreases post-operative pain and opioid consumption.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Sí = 1
Incierto = 0,5
No relevante = 0
No = 0
La evaluación de los criterios de información evalúa la transparencia con la que los autores informan de las características metodológicas y del ensayo dentro de la publicación. La evaluación se divide en cinco categorías que se presentan a continuación.
4/4
Randomization
4/4
Outcome Measurements
2/4
Inclusion / Exclusion
4/4
Therapy Description
0/4
Statistics
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
El Índice de Fragilidad es una herramienta que ayuda en la interpretación de hallazgos significativos, proporcionando una medida de fuerza para un resultado. El Índice de Fragilidad representa el número de eventos consecutivos que es necesario añadir a un resultado dicotómico para que el hallazgo deje de ser significativo. Un número pequeño representa un hallazgo más débil y un número grande un hallazgo más fuerte.
¿Por qué se necesitaba ahora este estudio?
Non-steroidal anti-inflammatory drugs can be used preoperatively and postoperatively as an analgesic, but its use is often discontinued prior to surgical treatment due to the belief that it increases perioperative blood loss. COX-2 inhibitors, a form of non-steroidal anti-inflammatory drug (NSAID), can be used for pain management, but there is uncertainty on its positive and negative effects. This study examines the effect of Celecoxib, a COX-2 inhibitor on perioperative and postoperative outcomes (blood loss, pain, analgesic requirement, range of motion and other subjective outcomes) in total knee replacement (TKR).
¿Cuál era la pregunta principal de la investigación?
What are the clinical and subjective perioperative and postoperative outcomes of Celecoxib (a COX-2 inhibitor) in patients undergoing total knee replacement (TKR) surgery?
- There were no significant differences seen in total, drainage or hidden blood loss between the intervention (Celecoxib) and placebo group. The total blood loss for the placebo group was 810 mL compared to 733 mL for the Celecoxib group. (95%CI= -1.6-11.6)
- The intervention group reported 30% lower pain scores compared to the placebo group during the first 4 weeks postoperatively.
- The intervention group also reported lower opioid consumption postoperatively (6 SD 6 mg vs. 10 SD 7 mg; 95% CI -9.5 to -2.5).
- At the 1-year follow-up, no effect was seen on range of motion, pain, and subjective outcomes.
- No deep infections or wound complications were seen during the first year postoperatively, but one patient from the placebo group sustained a bilateral deep vein thrombosis at 1 month postoperatively. The patient was treated successfully with warfarin.
- KOOS values improved from preoperation measurements in both groups at 3 and 12 months, but the difference between groups was not significant
¿Qué es lo que más debo recordar?
The use of Celecoxib did not induce increased blood loss perioperatively, but reduced postoperative pain after total knee replacement (TKR) surgery. At the one-year follow-up, pain, range of motion and subjective outcomes (KOOS score) did not improve following the postoperative use of Celecoxib.
¿Cómo afectará esto al cuidado de mis pacientes?
Patients undergoing total knee replacement (TKR) may find short-term pain relief postoperatively when taking Celecoxib. However, significant results/improvements may not be seen at 1 year. Further studies are being performed by the authors to examine the effect of Celecoxib on early prosthesis fixation.
DESCARGO DE RESPONSABILIDAD
El contenido de esta página tiene únicamente fines informativos y no pretende sustituir el consejo, diagnóstico o tratamiento médico profesional. Si necesita tratamiento médico, busque siempre el consejo de su médico o acuda al servicio de urgencias más cercano. Las opiniones, creencias y puntos de vista expresados por las personas sobre el contenido que se encuentra en esta página no reflejan las opiniones, creencias y puntos de vista de OrthoEvidence.
0 de 4 artículos mensuales GRATIS desbloqueados
